Fig. 2: Quantifying how 65 LNPs delivered mRNA delivery to 14 cell types in vivo, and subsequent in vivo structure-function analysis.
From: Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo
a LNPs were formulated to carry a unique DNA barcode and Cre mRNA. The 65 LNP pool was then administered to Ai14 mice. After 3 days %tdTomato+ cells were quantified in b multiple cell types in the liver, spleen, lung, and kidney (Average ± SEM, N = 4/group). Source data are provided as a Source Data file. c Normalized delivery for all 65 LNPs, averaged across all samples. Unencapsulated DNA barcode, acting as a negative control (-Ctrl), was delivered into cells less efficiently than barcodes encapsulated by LNPs. d Normalized delivery of LNPs formulated with each PPZ lipid, average ± SD. e Encapsulation efficiencies and diameters for LNPs formulated with PPZ-A10, cholesterol, C18PEG2K, and DOPE at a ratio of 35:46.5:2.5:16. f Fold enrichment calculated based on different lipids. g Encapsulation efficiencies of LNPs formulated with PPZ-A10, cholesterol, C18PEG2K, DOPE at four molar ratios; ratio 1 = 30:30:1:39; ratio 2 = 35:46.5:2.5:16; ratio 3 = 45:39.5:2.5:13; ratio 4 = 50:35:2.5:12.5, average ± SEM. h Fold enrichment calculated based on different ratios. i Fold enrichment calculated for cholesterol and 20□-OH cholesterol. j Fold enrichment calculated for C14PEG2K and C18PEG2K.
